AQST vs LVTX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
AQST Captures Institutional Edge (2โ1 Pillars ยท 3โ5 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Aquestive Therapeutics, Inc. Common Stock (AQST) driven by superior Growth & Margin, Options & Structure while LVTX counters with relative strength in Momentum & Technical. Fundamentally, AQST trades at N/M Forward P/E with -114.1% operating margin (-41.0% YoY revenue) versus LVTX at N/M Forward P/E and -431.9% operating margin (+1313.6% YoY). In options structure, AQST sits in BREAKDOWN (64th %ile IV; Dealer Gamma Walls on Pro) against LVTX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | AQST | LVTX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $465.7M | $45.8M | Larger Scale | AQST |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -41.0% | +1313.6% | Higher Growth | LVTX |
| Operating Margin (TTM) Profitability | -114.1% | -431.9% | Higher Margin | AQST |
| Net Profit Margin Profitability | -162.3% | 0.0% | Higher Margin | LVTX |
| Return on Equity (ROE) Capital Efficiency | 0.0% | -101.5% | Higher ROE | AQST |
| 52-Week Range Position Momentum | 14% ($3โ$7) | 77% ($1โ$2) | Stronger Trend | LVTX |
| Beta / 30D Volatility Risk Regime | 0.89ฮฒ ยท 56% Vol | -0.02ฮฒ ยท 49% Vol | Lower Realized Risk | LVTX |
| Unified Institutional Score Composite Signal | 62.9 / 100 (BUY) | 67.0 / 100 (BUY) | Higher Composite | LVTX |